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Abstract
Background: Anxiety is a common diagnosis in children with autism spectrum disorder (ASD). One key mechanism
underlying anxiety is intolerance of uncertainty, which is a tendency to react negatively on an emotional, cognitive,
and behavioural level to uncertain situations and events. We developed the first intervention programme
specifically targeting intolerance of uncertainty in children with ASD: Coping with Uncertainty in Everyday Situations
(CUES). CUES is a parent group intervention providing parents of children with ASD with strategies to increase
tolerance to uncertainty for their children in everyday situations. The principal aims of the current study are: 1)
evaluate the acceptability and feasibility of delivering CUES to parents who have a child with ASD and anxiety; and
2) inform the design of a fully powered trial.
Method: This is a feasibility and acceptability single-blind pilot randomised controlled trial comparing CUES
(intervention) to a brief psychoeducation, emotional literacy, and relaxation programme (enhanced services as
usual). Participants will be assessed at baseline and followed-up immediately post-treatment, and at 12 and 26
weeks post-treatment. Parents who have a child with ASD and anxiety (aged 6–16 years) will be invited to take part
in the study and written parental informed consent and child assent will be obtained. Participants will be recruited
from the National Health Service mental health teams in the UK. Sixty participants will be randomised to either
intervention or enhanced services as usual in a 1:1 ratio.
Discussion: The present study will provide evidence on the acceptability of the CUES intervention to parents and
children, and the feasibility of recruitment and delivery to inform the design and sample size for a full-scale
randomised controlled trial. Qualitative data will be obtained to understand how feasible CUES is for families, and
the experiences of participants regarding their experiences of the intervention.
Trial registration: ISRCTN, ISRCTN10139240. Registered on 14 May 2018.
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Background
Mental health, and specifically anxiety, is amongst the top
five research priorities for future autism spectrum disorder
(ASD) research [1]. Approximately 50% of children with
ASD experience high anxiety, congruent with an anxiety
disorder [2, 3], which significantly impacts on everyday life
for them and their families. Anxiety is a major risk factor
for mental health difficulties in adulthood, including sui-
cidal thoughts and behaviours [4]. When present, anxiety
in individuals with ASD is often complex, encompassing
features of a range of concurrent anxiety disorders, as well
as atypical presentations [5, 6]. Therefore, treatment tar-
geting the underlying mechanisms rather than specific
symptoms is likely to be necessary and may be more ef-
fective. One key mechanism is intolerance of uncertainty
(IU). IU is a ‘broad dispositional risk factor for the devel-
opment and maintenance of clinically significant anxiety’
[7]. It involves the ‘tendency to react negatively on an
emotional, cognitive, and behavioural level to uncertain
situations and events’ [8].
Studies of people with ASD suggest that IU is a trans-
diagnostic construct associated with a range of anxiety
disorders [9–13]. Importantly, intervention studies with
neurotypical individuals suggest that a reduction in IU is
associated with a reduction in anxiety and improvements
in everyday functioning (see, for example, [14]). The role
of IU in anxiety in typically developing adolescents [15–
17] and children [18, 19] has been increasing, and it is
argued that cognitive behavioural treatments, which em-
phasise treating the cognitive process rather than the
cognitive content of anxiety, specifically by aiming to in-
crease the tolerance of patients for uncertainty, achieve
more sustainable change [20, 21]. Research has con-
firmed the utility of such protocols in reducing anxiety
in adults and children without ASD [22–25].
Recently, IU has been associated with some of the core
characteristics of ASD [26–28]. Restricted and repetitive
behaviours, such as insistence on sameness, inflexible
adherence to routines, and difficulty tolerating change,
have been linked with anxiety in ASD since the earliest
descriptions of the disorder [29] and bear a conceptual
resemblance to IU; that is, avoidance of unexpected
events and desire to make life as predictable as possible
[30]. There is also evidence that IU has a central role in
the relationship between ASD and anxiety. Boulter et al.
[11] reported significant relationships between IU and
anxiety in children with ASD, and their results suggested
that, compared with matched neurotypical controls, IU
levels account for the increased anxiety observed in chil-
dren with ASD. Wigham et al. [10] examined the role
that IU has in pathways between sensory processing dif-
ficulties, anxiety, and restricted and repetitive behaviours
in ASD. These relationships were mediated by IU, indi-
cating the important role IU may have in the interaction
between anxiety and ASD traits. Chamberlain et al. [12]
reported associations between shared neurobehavioural
mechanisms in ASD and anxiety, indicating specific ave-
nues for intervention targeting IU. Rodgers et al. [31]
developed and validated a child self-report and parent-
report measure of anxiety for children with ASD (the
ASC-ASD). Using factor analytic techniques, Rodgers
identified four reliable anxiety subscales, including an
uncertainty scale. Hodgson et al. [32] undertook focus
groups with parents of children with ASD exploring the
concept of IU. Parents differentiated IU from dislike of
change and from fear, discussed examples of IU and its
impact on their children, and suggested that IU is a rec-
ognisable and important construct associated with anx-
iety distinguishable from but related to features of ASD.
Although many of the studies come from the Newcastle
group, in an independent multisite study Keefer et al. [9]
demonstrated that high levels of pretreatment IU signifi-
cantly predicted poorer treatment response in a group of
children with ASD receiving treatment for anxiety. Neil
et al. [33] further replicated that IU is a relevant con-
struct related to sensory sensitivities and anxiety in chil-
dren with ASD. Finally, Kerns et al. [34] in a discussion of
the differential diagnosis of anxiety disorders in ASD re-
port that fears associated with uncertainty may be an im-
portant mechanism in the development and maintenance
of anxiety in ASD. In conclusion, this evidence indicates
that IU appears to be an important mechanism in the de-
velopment and maintenance of anxiety for children with
ASD and an appropriate target for intervention.
Therefore, we developed the first intervention
programme specifically targeting IU in children with
ASD: Coping with Uncertainty in Everyday Situations
(CUES) [5]. CUES is an 8-week parent group interven-
tion that provides parents of children with ASD with
strategies to increase tolerance of uncertainty for their
children in everyday situations. Our CUES development
project [5] provided preliminary evidence that CUES is
feasible and acceptable to families, that parents found it
helpful to work with clinicians to develop a range of
strategies to tackle uncertainty in everyday contexts that
they can support their child to utilise, and parents and
children reported beneficial effects on everyday func-
tioning. We now plan to conduct a feasibility and ac-
ceptability randomised pilot trial of CUES. The SPIRIT
checklist is included as Additional file 1.
Methods/design
Trial design
This is a feasibility and acceptability pilot randomised
controlled trial of a parent group-based intervention
aimed at increasing tolerance to uncertainty in children
with ASD: Coping with Uncertainty in Everyday Situa-
tions (CUES) [5].
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Aims
We aim to: 1) ascertain whether CUES is feasible to de-
liver through UK National Health Service (NHS) services
by trained therapists, and is acceptable and well received
by families; 2) establish the rate of referrals from child
mental health teams in two NHS Trusts; 3) record the
proportion of families who agree to participate and the
proportion who complete all sessions, and to explore
suitable methods of data collection and outcomes in re-
lation to health services costs and costs to families of
children with IU; 4) investigate whether treatment fidel-
ity can be maintained across therapists; 5) record re-
sponse rates for completion of outcome measures; 6)
obtain participant feedback on the programme and val-
ued outcome measures; 7) determine the acceptability/
credibility of our active control group procedures; 8) in-
vestigate whether the families who participate in CUES
have greater reduction in real-life IU and anxiety than
children receiving enhanced services as usual; 9) de-
scribe variability in responses to CUES in children re-
ferred from NHS services; and 10) monitor whether any
treatment effects persist 6 months post-treatment (pri-
mary endpoint).
Setting and participants
Sixty parent participants will be recruited via NHS ser-
vices (including diagnostic clinics and Child and Adoles-
cent Mental Health Services). This number is based on
recommendations for good practice in feasibility studies
[35]. Parents are eligible for study entry if their child
meets the following criteria: 1) a diagnosis of ASD; 2) aged
6–16 years; 3) experiences some anxiety; 4) no intellectual
disability or mild-to-moderate intellectual disability; and
5) have sufficient language ability to complete appropriate
outcome measures (with assistance if required).
Parents themselves will have sufficient spoken and
written English to provide written informed consent,
complete assessments, and participate in the interven-
tion. Parents are not eligible for study entry if their child
meets the following criteria: 1) no diagnosis of ASD
diagnosis; 2) experiences severe and complex anxiety
disorder (based on the clinical judgement of clinicians);
3) has severe intellectual disability; or 4) has complex
health conditions.
Furthermore, children of parents who have significant
mental health difficulties will not be eligible to participate.
Participant identification and recruitment process
Families will be identified via NHS services. At NHS ser-
vices, clinicians at the participating identification centres
will be provided with information about IU to ensure fa-
miliarity with the construct to enable them to introduce
the study to families. Clinicians will identify children fit-
ting the inclusion criteria, discuss the study with them,
and if interested give them study packs (Fig. 1). Inter-
ested parents will complete an expression of interest
form that will be sent to the research team. The research
team will then contact parents to arrange a face-to-face
meeting to discuss the study, what participation involves,
answer any questions they may have, and arrange writ-
ten informed consent. Baseline data will be collected at
this point, prior to randomisation.
Information provided to participants makes it clear
that they do not have to participate in the trial and their
decision will not affect their treatment. The participant
can withdraw from the study at any time, which will not
affect any further NHS treatment or services.
Treatment
Intervention arm: CUES
CUES is an 8-week manualised programme [5] that pro-
vides parents of children with ASD the strategies to in-
crease tolerance to uncertainty in everyday situations in
their children. It was devised in partnership with par-
ents. The key goal of the programme is to increase the
child’s tolerance to uncertainty, reduce negative beliefs
about uncertainty, and develop a more flexible approach
to uncertainty. A parent-mediated intervention is appro-
priate because it provides parents with strategies that
they can utilise with their child across a range of every-
day contexts. It also supports generalisation of these
strategies outside of the clinic setting, as well as counter-
ing well-meaning, understandable but ultimately unhelp-
ful/counter-productive strategies used by parents to try
to build certainty around the child, when certainty is not
realistically possible. Thus, working with parents in-
creases the translational potential of the intervention.
Parents will attend the programme, with two therapists
with expertise in ASD facilitating each group. Each
group will include approximately ten parents and ses-
sions will take place weekly for 8 weeks. Each session
will be 2 h in duration. ‘At home’ activities will be set
each week for parents and children to complete between
sessions. The programme begins with a focus on the de-
velopment of understanding of uncertainty in everyday
life, the nature and impact of IU, and promotes the use
of strategies to flexibly manage IU across a range of set-
tings. The intervention helps parents to recognise IU
and identify potential developmental and environmental
factors that may trigger IU for their child. It further tea-
ches parents to plan and use appropriate strategies
aimed at increasing their child’s tolerance of uncertainty.
Each parent will be provided with weekly materials and
individual support to identify strategies to address a
chosen target IU situation. This target situation is the
focus for parents to practise the new strategies with their
child, thus ensuring that strategies are individually tailored
for each child and are developmentally appropriate. The
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group situation provides extensive opportunities for mu-
tual learning and support. The CUES intervention has in-
corporated and synthesised components of existing good
practice in relation to anxiety treatment for children with
ASD. It provides the opportunity for parents to develop
an understanding of IU and its impact, to try out various
Clinicians at participant identification sites identify families 
fitting the inclusion criteria on their caseloads and waiting lists.
Clinicians introduce the trial and families receive a study pack 
which includes a parent information sheet, examples of IU, a 
young person’s information sheet, and an expression of interest 
form. 
If parents are interested, they complete the expression of interest 
form and a) post it to the researcher, or b) return it to the clinician 
who contacts the researcher to arrange collection.  
The researcher reviews the expression of interest form and 
contacts parents to answer any questions and book a face-to-face 
meeting at the parents’ home.  
If parent is still eligible and interested, they are consented and 
baseline measures are completed (usually over two visits). The 
participant is then randomised to CUES or Understanding 
Autism.  
Participant undergoes trial treatment (either CUES or 
Understanding Autism). 
CUES: 8 x 2 hour sessions
Understanding Autism: 2 x 2 hour sessions  
Participant completes follow-up questionnaires (postal) and IU 
scenarios (telephone) immediately post-treatment.
Participant completes 12 week post-treatment follow-up 
questionnaires (postal) and IU scenarios (telephone).
Participant completes 26 week post-treatment follow-up 
questionnaires (postal) and IU scenarios (telephone).
Participant is interviewed by the non-blinded researcher to 
explore acceptability and feasibility.
Fig. 1 Participant identification, recruitment, and follow-up procedure. CUES Coping with Uncertainty in Everyday Situations, IU intolerance
of uncertainty
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strategies, and provides opportunities for discussion, mu-
tual support and sharing of ideas, and experiences and
strategies, importantly building parents’ knowledge and
confidence to support their child at home to develop a
more flexible approach to uncertainty.
Therapists delivering CUES are trained in the skills
needed to deliver the programme through two training
sessions (5 h in total). To ensure the intervention is being
delivered as intended, with high fidelity to the manual, the
principal investigator (JR) and the clinical lead (VG) will
undertake supervision and monitoring of the quality of
parent group sessions by video, providing timely feedback
to group leaders. Weekly supervision of the therapists will
be conducted by JR and VG. Treatment fidelity will be
maintained and investigated from multiple standpoints,
including supervisor feedback, and formally by observer
ratings of recordings of the group sessions.
Enhanced services as usual arm: Understanding Autism
Understanding Autism will comprise two parent group
sessions. Each session will be 2 h in duration. Parent
group-based interventions provide parents with the op-
portunity not only to develop knowledge and skills in re-
lation to the treatment target (in this case IU), but also
provide opportunities for discussion, mutual support,
and sharing of ideas, a process which parents tell us they
value. Given the feasibility and acceptability aims of the
current study, we were concerned that offering families
in the control arm no opportunity to meet together as a
group might significantly bias favourable responses in
relation to acceptability towards the CUES intervention
arm. In addition, treatment as usual is highly variable
and thus the introduction of a two-session programme
for the enhanced services as usual arm enables us to
provide parents with some common content, and cred-
ibility/expectancy will be rated for both arms, whereas
services as usual cannot be rated; this creates a greater
level of equipoise than treatment as usual. There is cur-
rently no equivalent eight-session parent support group
available to parents of children with ASD within this age
range, and parents in the control arm receive a two-
session Understanding Autism programme. This enables
parents randomised to the control arm to have experi-
ence of a parent group setting. Both arms will continue
to receive treatment as usual, which will be recorded on
the demographics form.
The group will focus on psychoeducation, social com-
munication, repetitive behaviours, and making and keep-
ing friends. There are opportunities for parents to
engage in group discussion regarding their experiences,
such as the ASD diagnostic process.
Group leaders for Understanding Autism have exten-
sive knowledge on ASD and have a track record of in-
volvement in research and community outreach. The
materials were developed in collaboration with the re-
search team. They will receive weekly supervision with
the principal investigator. Further, to ensure Under-
standing Autism is being delivered as intended (without
reference to anxiety or IU), the principal investigator
(JR) will monitor the quality of parent group sessions by
video, providing timely feedback to group leaders. Fidel-
ity will be formally assessed by an independent rater uti-
lising a fidelity checklist and recordings of the group
sessions. The control group will not have access to the
intervention after the trial.
Strategies to maintain adherence
A number of strategies will be utilised to improve adher-
ence in terms of attendance at the intervention sessions
and completion of the follow-up assessments. These in-
cludes written information about the venues for the ses-
sions, in the case of absence from a session the materials
for the session are posted to the participant to be re-
ceived during the week of absence and a telephone call
arranged between one of the therapists and the parents
to ensure they have received the materials, determine if
they have any questions, and encourage attendance at
the next session. Parents are sent reminder emails,
followed up with a telephone call if follow-up question-
naires have not been received. All parents receive regular
newsletters about the study, along with seasonal greet-
ings cards to encourage continued participation.
Harm
Based on the development study for CUES [5] adverse
events or unintended effects are not anticipated. How-
ever, if a clear safeguarding concern arises this will trig-
ger an immediate response. The staff delivering the
programmes are employees of the sponsoring Trust and
will follow Trust protocols. In addition, therapists will
receive weekly supervision from the principal investiga-
tor, on the same day as the intervention session takes
place, and reporting of any unintended effects or adverse
events is included as a standard item on the supervisory
agenda. If any such events are identified, they will be dis-
cussed with the clinical lead which will result in action ap-
propriate to the situation following the Standard
Operating Procedures of the sponsor (Northumberland
Tyne and Wear NHS Foundation Trust (NTW)), which
are compliant with Good Clinical Practice (GCP) and
Health Research Authority (HRA) guidelines for safety
reporting. All such events will be recorded in the site file.
Confidentiality and access to data
All the data collected as part of the study will be kept
strictly confidential and in accordance with the General
Data Protection Regulation (GDPR). Participants are pro-
vided with detailed information relating to confidentiality
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in the participant Information Sheet. Northumberland
Tyne and Wear NHS Foundation Trust (NTW) is the
sponsor and will act as the data controller. The study is
being led and managed by Newcastle University, who are
acting as a data processor. NTW and Newcastle Univer-
sity will keep identifiable information about participants
until 3 years after the youngest child in the study reaches
18 years old. The local study team at NTW and New-
castle University will use participants’ names and con-
tact details to contact them about the research study,
and make sure that relevant information about the
study is recorded for their child’s care, and to oversee
the quality of the study. Individuals from NTW, New-
castle University, and regulatory organisations may
look at the research records to check the accuracy of
the research study. The only people who will have ac-
cess to information that identifies participants will be
people who need to contact them about the study or
audit the data collection process. All information will
be stored in a secure and locked office, and on a
password-protected database. Any information which
leaves the hospital or university sites will have names
and addresses removed (anonymised) and a unique
code will be used. Personal data (name, address,
email, telephone number) will be kept after the end
of the study so that we are able to contact partici-
pants about the findings of the study.
Randomisation and blinding
Participants are randomised on a 1:1 basis to receive ei-
ther CUES or Understanding Autism, without stratifica-
tion. Randomisation occurs online through Sealed
Envelope (https://www.sealedenvelope.com/). Partici-
pants will be aware of group status due to the nature of
the intervention, but the primary outcome assessor will
be blind to group allocation although, despite instruction
not to do so, participants could unwittingly break blind-
ness if they reveal details about the intervention at post-
treatment assessment.
Procedure
The researcher will meet with the participant at home to
explain the study, answer questions, obtain informed
consent (and assent from the child), and undertake the
baseline characterisation and target uncertain situation
interviews. This may be split into two visits depending
on logistics (e.g., parents’ availability) and the length of
time the interviews take, as this will vary between partic-
ipants. Prior to the first visit, the assessments in ques-
tionnaire format are posted to the parent to complete.
These are collected once the participants have been con-
sented at the home visit(s).
Primary and secondary outcomes
We are aiming to determine whether CUES is feasible to
deliver through NHS services by trained therapists, and if
it is acceptable and well received by families. Also, we will
investigate whether successfully targeting IU will result in
an increased tolerance to uncertainty and a downstream
reduction in a range of anxiety disorder symptoms, along-
side an increase in children’s social participation as evi-
denced by the respective outcome measures. In addition,
we will explore whether participation in CUES will have a
beneficial effect on parental wellbeing.
Baseline characterisation
The characteristics and functional abilities of the child
with ASD will be measured by the Social
Communication Questionnaire (SCQ; [36]) (parent
reporting on child). This is a 40-item questionnaire
which is used internationally and has high sensitivity
and specificity for an ASD diagnosis [36]. We will also
use the Vineland Adaptive Behaviour Scales III (VABS
III; [37]) (parent reporting on child). The number of
items depends on the child’s developmental level. It has
demonstrated excellent internal consistency (α = 0.90 to
0.98) and content, construct, and concurrent validity [37].
The anxiety characteristics of the child with ASD will
be measured with the Anxiety Disorders Interview
Schedule — Autism Spectrum Addendum (ADIS-ASA;
[38]) (parent reporting on child). The number of items
depends on the child’s symptoms of anxiety. It is a
reliable measurement of comorbidity (intraclass
correlation (ICC) = 0.85–0.98; κ =0.67–0.91) as well as
ambiguous anxiety-like symptoms (ICC = 0.87–95, κ =
0.77–0.90) in children with ASD. Convergent and dis-
criminant validity were supported for the traditional
anxiety symptoms on the ADIS/ASA, whereas conver-
gent and discriminant validity were partially supported
for the ambiguous anxiety-like symptoms. We will all
interview the parent to obtain information about the
child’s current treatment and other health service
usage; concurrent life events that may influence mood;
perceived impact of anxiety on the child’s education
and participation in everyday events; and impact of the
child’s anxiety on other members of the family (parent
reporting on child).
Feasibility and acceptability outcomes
The outcomes are acceptability of all aspects of the
trial (including outcome measures, acceptability of
intervention materials and methods, use of strategies
outside of sessions, and any perceived benefits after
treatment) and feasibility (including experience of
recruitment, randomisation, and visits to the home).
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These will be obtained via parent interview (parent
self-report and parent reporting on child) and the
Credibility and Expectancy Questionnaire [39] (parent
self-report). The CUES group completes a 10-item
questionnaire and the Understanding Autism group
completes a 6-item questionnaire. This has demon-
strated high internal consistency within each factor
(α = 0.86) and good test–retest reliability. The expect-
ancy factor predicts outcome on some measures,
whereas the credibility factor is unrelated to outcome
[39]. We will also conduct interviews with therapists.
Main research outcome
The main research outcome is to target uncertain
situations that cause the child to experience anxiety
due to IU (parent reporting on child) using a target
behaviour rating. Parents will be asked to identify two
target real-life situations that might cause their child
significant IU (method validated in our pilot work [5]),
one situation that their child would like to do but cur-
rently cannot do or not do consistently (e.g. playing
with friends in the neighbourhood), and one situation
that is appropriate and necessary for them to do due to
normal developmentally appropriate educational, social
participation, or inclusion outcomes (e.g. attending
swimming lessons). Through a semistructured inter-
view, parents will be asked what about the situation is
uncertain, how often it occurs, the child’s reaction
(symptoms and intensity), whether the child worries
about the situation in advance, and how it interferes
with daily functions and activities for the child and the
family. This can include adaptations to family life, the
emotional impact, and the impact on relationships
(child, siblings, peers, school, family, how they feel
about themselves, and development of autonomy). The
interview schedule may be an iterative process to en-
sure the situation involves IU and is appropriate for
CUES in that it is current and presents an ongoing ra-
ther than a ‘one-off ’ situation.
This assessment protocol is based on that used by The
Research Unit on Paediatric Psychopharmacology and
Psychosocial Interventions [40] and has been used in
previous anxiety and other treatment trials (e.g. [41,
42]). The IU target situations will be rated on a nine-
point scale of improvement/deterioration independently
by a panel of experienced clinicians. The top 3 points
will define ‘a responder’. Arnold et al. [40] report ICC
of 0.895 for a panel of five experts.
Secondary research outcomes
IU will be measured with the Intolerance of
Uncertainty Scale (IUS-P and IUS-C; [43]) (parent
reporting on child and (where possible) child self-
report). Both are 12-item questionnaires. Both child (C)
and parent (P) measures show acceptable to excellent
internal consistency in ASD (α = 0.78 and 0.90, respect-
ively) and typically developing groups (α = 0.76 and
0.91, respectively). We will also use the Intolerance of
Uncertainty Scale (IUS-12; [7]) (parent self-report).
This is a 12-item questionnaire, which has excellent in-
ternal consistency in a clinical sample (α = 0.91) and
community sample (α = 0.92). The average inter-item
correlation was 0.48 [7].
Anxiety will be measured by three items. The Screen
for Child Anxiety Related Disorders (SCARED; [44])
(parent reporting on child) is a 41-item questionnaire
which has demonstrated good internal consistency (α =
0.74–0.93), test-retest reliability (ICC 0.70–0.90), and
discriminative validity, both between anxiety and other
disorders and within anxiety disorders [44]. The Anx-
iety Scale for Children — ASD – Parent and Child ver-
sions (ASC-ASD; [31]) (parent reporting on child and
(where possible) child self-report) both (parent and
child versions) have 24 items, and have demonstrated
good to excellent internal consistency (α = 0.85–0.91),
validity with measures (including sensory processing
hypersensitivity, repetitive behaviours, depression, and
anxiety), and 1 month test–retest reliability (r = 0.84,
ICC = 0.84 for parent; r = 0.82, ICC = 0.82 for child)
[31]. The Depression, Anxiety and Stress Scale (DASS;
[45]) (parent self-report) is a 42-item questionnaire.
This has acceptable reliability (α = 0.84–0.91), and con-
vergent and discriminant validity [45].
Participation and enjoyment will be assessed with the
Children’s Assessment of Participation and Enjoyment
(CAPE; [46]) (child self-report). This is a 55-item ques-
tionnaire, which has demonstrated good internal
consistency (α = 0.30–0.62, which is expected due to
the environmental, family, and child factors that affect
participation), test–retest reliability (ICC = 0.64–0.86),
and sufficient content and construct validity [46].
Self-efficacy will be assessed with the Parent self-
efficacy [47] (parent self-report). This is a 15-item
questionnaire that ask parents to rate their confidence
and self-efficacy in relation to behaviours targeted in
clinical studies (in this case anxiety and IU-related be-
haviours). It is widely used for parent-mediated inter-
ventions and there are reliability and validity data
available.
Reactions to uncertainty and confidence will be
measured using a bespoke questionnaire administered
to parents each week of the CUES programme (parent
reporting on self and child).
Resource use will be assessed with a bespoke
questionnaire given to parents measuring health
resource use associated with IU in their child.
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Time and travel costs will be assessed with a bespoke
questionnaire administered to parents measuring the
travel costs and travel time associated with managing
their child’s IU.
Data collection and data management
Figure 2 details the information collected at different
time points. To reduce burden for the family, follow-up
assessments using questionnaire measures will be com-
pleted by post and the IU scenarios outcome measure
will be rated by parents during follow-up telephone
semistructured interviews with the blinded researcher.
Northumberland Tyne and Wear NHS Foundation Trust
may audit the data collected. Data collected on paper as-
sessment tools will be entered onto a secure statistical
analysis software system. A unique trial number will be
used to identify participants on all paper data collection
forms throughout the duration of the trial. No
participant-identifiable data will leave the study site. The
quality and retention of study data will be the responsi-
bility of the principal investigator. All study data will be
retained in accordance with the latest Directive on Good
Clinical Practice (2005/28/EC) and local policy. Staff in-
volved in the conduct of the trial, including the principal
investigator, Trial Management Group and therapist staff
involved in screening and intervention, will have access
to the site files. Clinical information shall not be released
without the written permission of the participant, except
as necessary for monitoring and auditing by the Sponsor,
its designee, regulatory authorities, or the REC. The
principal investigator and staff involved in this trial may
not disclose or use for any purpose, other than perform-
ance of the trial, any data, record, or other unpublished,
confidential information disclosed to those individuals
for the purpose of the trial.
Planned analyses
Sydes and colleagues [48], who reviewed requirements
for data monitoring committees (DMCs), concluded that
DMCs are recommended when trials have any of the fol-
lowing features: trials on high-profile topics that are a
focus of community concern, that will be used to seek
regulatory approval or that are likely to profoundly affect
clinical practice; trials with serious safety concerns, un-
known risks or that are implemented in vulnerable pop-
ulations; and trials where independent monitoring is
needed because of double-blind treatment assignment or
long-term follow-up or because the sponsoring company
does not have standard operating procedures. DMCs
may not be needed: 1) for trials that are of short dur-
ation (where it may not be feasible to convene a DMC
in a timely fashion to review the data); 2) for trials with
known risks that are minimal; 3) for trials in which the
objective is to demonstrate principles (such as in early-
phase clinical trials); or 4) for trials on behavioural or
administrative issues. In the current case, given the ac-
ceptability and feasibility aims where we are constantly
monitoring events that could relate to acceptability and
feasibility such as nonattendance (for any reason) and, if
not informed of a reason, this is followed-up, coupled
with the short duration, minimal risks, and the parent-
delivery of treatment, it was determined that a DMC
was not required. In this case, data management will be
discussed at Trial Steering Committee meetings.
As this is a feasibility study, analyses will be mainly de-
scriptive, and no interim analysis will be undertaken.
Formal power calculations are not appropriate as the
study is not designed to test for a difference between
treatments. Feasibility will be explored by examining: 1)
the number of families who consented, their attendance,
and complete data at 6 months; and 2) that qualitative
data support the acceptability of CUES by the majority
of parents and clinicians.
We will also undertake some preliminary analysis of
treatment effects. As a randomised controlled trial, pri-
mary analysis will be based on the intention-to-treat
principle with analysis based on groups allocated at ran-
domisation and all randomised families included. The
extent of missing data will be assessed. Rates will be cal-
culated as defined and reported with 95% confidence in-
tervals. At baseline and by group, the distribution of all
variables will be examined and summarised by measures
of central location and spread and reported with 95%
confidence intervals. Baseline categorical variables will
be tabulated and percentages reported with 95% confi-
dence intervals. The difference in mean change for all
outcome measures will be examined between the groups
from baseline to each of the two time points with ac-
companying 95% confidence intervals. Evidence of clus-
tering and/or contamination will be explored. Such
results will be interpreted cautiously because of the size
of the study and the possible imbalance in prerandomi-
sation baseline covariates. The relationship between
baseline covariates and outcome measures will be exam-
ined graphically and quantified appropriately depending
on their distribution.
While no formal economic evaluation will be under-
taken at this stage, questionnaires have been designed in
conjunction with patient representatives which will
measure resource use associated with managing IU. The
data gathered from these questionnaires will provide in-
formation about healthcare resource use and personal
costs to families which will aid the design of a potential
future economic evaluation associated with a full trial.
Numbers of families who express interest, continue to
treatment, and who complete treatment will be re-
corded. When families do not participate/complete
treatment, the reasons for this will be investigated, if
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appropriate and where possible, through brief telephone
interviews or visits to families. The study team and the
health economist will advise on the content of the inter-
view schedule.
When appropriate, interviews will be recorded, tran-
scribed, double-coded, and analysed using thematic
analysis [49].
Dissemination plan
Dissemination of the findings will be undertaken in a
number of ways. Co-applicants representing the autism
community (DG and MO) will review the findings
alongside the Patient and Public Involvement group and
other members of the research team and assist with
“translating” the main findings and implications for
Measures Baseline During 
Treatment
Immediately 
post-
treatment
6 weeks 
post-
treatment
12 weeks 
post-
treatment
26 weeks 
post-
treatment
Gender X
Age X
Source of referral X
Contact information X
Demographic information X
Time and travel information X
Resource information X X X X
ADIS-ASA X
SCQ X
VABS III X
Target Uncertain Situation X X X X
IUS-P X X X X
SCARED X X X X
ASC-ASD Parent version X X X X
IUS-Ca X X X X
CAPEa X X X X
ASC-ASD Child versiona X X X X
Parent self-efficacy X X X X
IUS-12 X X X X
DASS X X X X
Credibility and Expectancy 
questionnaire
X (CUES 
sessions 2, 5, 
8; 
Understanding 
Autism 
session 1)
Reactions to uncertainty 
and confidence
X (all CUES 
sessions)
Fidelity checklist X (all 
sessions)
Date of each scheduled 
CUES or Understanding 
Autism session and whether 
the session was attended
X
Reasons for non-attendance 
or early withdrawal
X
Acceptability and feasibility 
interview
X
a Indicates that the measure will be completed by the child (with help, if needed).
Fig. 2 Time points at which measures and data are collected. ADIS-ASA Anxiety Disorders Interview Schedule — Autism Spectrum Addendum,
ASC-ASD Anxiety Scale for Children — Autism Spectrum Disorder, CAPE Children’s Assessment of Participation and Enjoyment, CUES Coping with
Uncertainty in Everyday Situations, DASS Depression, Anxiety and Stress Scale, IUS-C Intolerance of Uncertainty Scale Child, IUS-P Intolerance of
Uncertainty Scale Parent, SCARED Screen for Child Anxiety Related Disorders, SCQ Social Communication Questionnaire, VABS III Vineland
Adaptive Behaviour Scales III
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dissemination; a film will be made about the findings
and posted on research group websites with links dis-
tributed during dissemination events. A series of reports
will be written in an accessible and inclusive manner for
a lay audience, including reports and newsletters for aut-
istic people and their families, professionals and com-
missioners, and other agencies. Some versions will be
prepared using ‘easyread’ to maximise accessibility and
will be available in both written and video format. A
feedback event will be hosted to present findings to fam-
ilies. Findings will be presented at academic meetings
and written up for open-access peer-reviewed journals.
UK multidisciplinary team clinicians will be informed
through presentations at relevant professional meetings
and conferences. Articles will be written for the profes-
sional organisations’ newsletters.
Discussion
Anxiety affects approximately 50% of children with
ASD. It significantly impacts on the everyday life of fam-
ilies and is a major risk factor for mental health difficul-
ties, including suicide, in adulthood. There is evidence
to suggest that IU plays a central role in the relationship
between ASD and anxiety (e.g. [11]). CUES aims to tar-
get IU by providing parents with strategies to manage
children’s IU and improve their everyday functioning.
Therefore, CUES has the potential to improve psycho-
logical outcomes for children with ASD and their fam-
ilies because it provides parents with strategies that they
can utilise with their child across a range of everyday
contexts.
The present study will provide data on the acceptabil-
ity of the CUES intervention as well as feasibility trial
data to inform the design and sample size for a full-scale
trial. In addition, qualitative data will be obtained to
understand how feasible CUES may be for families based
on participants’ experiences of the intervention.
Trial status
The first participant was consented to the CUES trial on
19 June 2018. Recruitment is planned to continue until
February 2019.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 120 kb)
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